Review of venom immunotherapy at a regional tertiary paediatric centre.
anaphylaxis
bee venom
immunotherapy
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
18
02
2022
received:
13
01
2022
accepted:
09
03
2022
pubmed:
14
4
2022
medline:
6
7
2022
entrez:
13
4
2022
Statut:
ppublish
Résumé
Bee stings can result in allergic reactions, including anaphylaxis. Venom immunotherapy (VIT) is a definitive cure for bee venom allergy, but controversy surrounds whether accelerated protocols are safe in children. Our primary aim was to assess the safety profile of ultra-rush bee VIT compared with conventional bee VIT at a regional paediatric tertiary centre. We also sought to evaluate the impact of both approaches on time and resource use. Data were collected retrospectively from 14 patients with bee venom allergy who were treated with ultra-rush or conventional bee VIT between 2013 and 2021 at John Hunter Children's Hospital. We compared VIT-associated adverse reactions and use of resources in both these groups. Overall, six patients received ultra-rush bee VIT and eight patients received conventional VIT. The ultra-rush group had a lower rate of systemic reaction (16%) compared with the conventional group (25%). One patient from the conventional group required adrenaline. Ultra-rush patients require fewer injections over a shorter time and fewer hospital visits to complete the protocol. Travel distance for families was significantly reduced. At our regional paediatric tertiary centre, ultra-rush bee VIT was a safe treatment option for children with bee venom allergy. It has many advantages over a conventional approach, especially for patients living in regional or remote areas.
Substances chimiques
Bee Venoms
0
Wasp Venoms
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1232Informations de copyright
© 2022 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Boros CA, Kay D, Gold MS. Parent reported allergy and anaphylaxis in 4173 south Australian children. J. Paediatr. Child Health 2000; 36: 36-40.
Cichocka-Jarosz E, Brzyski P, Tarczoń I, Jedynak-Wąsowicz U, Tomasik T, Lis G. Quality of life in parents of children and adolescents after systemic sting reactions. Ann. Agric. Environ. Med. 2019; 26: 315-21.
Krishna M, Ewan P, Diwakar L et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin. Exp. Allergy 2011; 41: 1201-20.
Golden DBK, Kagey-Sobotka A, Norman P, Hamilton R, Lichtenstein L. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. NEJM. 2004; 351: 668-74.
Australian Product Information - Albey Bee Venom (Apis mellifera). Stallergenes Australia Pty Ltd. Approved 28 April 2009, revised 30 May 2019.
Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): A safety study and risk factors. Clin. Exp. Allergy 2003; 33: 58-64.
Mosbech H, Muller U. Side-effects of insect venom immunotherapy: Results from an EAACI multicenter study. Eur J Allergy Clin Immunol. 2000; 55: 1005-10.
Mueller HL. Diagnosis and treatment of insect sensitivity. J. Asthma Res. 1966; 3: 331-3.
Köhli-Wiesner A, Stahlberger L, Bieli C, Stricker T, Lauener R. Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: Safety and tolerance. J. Allergy 2012; 2012: 1-5.
Steiß J, Lindemann H. Safety of modified ultra-rush venom immunotherapy in children. J Allergy Ther. 2013; 04: 4-6.
Nittner-Marszalska M, Cichocka-Jarosz E, Małaczyńska T et al. Safety of ultrarush venom immunotherapy: Comparison between children and adults. J. Investig. Allergol. Clin. Immunol. 2016; 26: 40-7.
Houliston L, Brookes I, Mallon DF, Golden DB. Venom immunotherapy. NEJM. 2004; 351: 2129-30.
Sturm GJ, Varga EM, Roberts G et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Eur J Allergy Clin Immunol. 2018; 73: 744-64.
Mackey L, Ziegler C, Smith A, Johannsen H. ASCIA-P45: Review of ultra-rush bee venom immunotherapy in children at flinders medical centre. Intern. Med. J. 2016; 46(S4): 18-9.
Diwakar L, Noorani S, Huissoon AP, Frew AJ, Krishna MT. Practice of venom immunotherapy in the United Kingdom: A national audit and review of literature. Clin. Exp. Allergy 2008; 38: 1651-8.
Golden D. Venom immunotherapy: Questions and controversies. Immunol. Allergy Clin. North Am. 2020; 40: 59-68.
ASCIA Venom Immunotherapy Guide Venom Immunotherapy A Guide for Clinical Immunology/Allergy Specialists. Available from: www.allergy.org.au/hp/papers [accessed 23 Oct 2021].